Maynard Um
-
-
-
-
-
-
-
Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) files mixed shelf
-
-
-
-
-
-
-
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
-
-
-
-
-
-
-
Barclays: 'We think dropping the question of '441 validity from the case is a major development'
-
-
-
-
-
-
-
RBC Capital Starts BridgeBio Pharma (BBIO) at Outperform
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $106 at Mizuho
-
-
-
-
-
-
-
TD Cowen comments on BridgeBio Pharma following positive infigratinib data
-
422,382 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

